Vaccinex Inc logo

Vaccinex Inc Share Price Today (NASDAQ: VCNX)

Vaccinex Inc share price is $0 & ₹0.00 as on 17 Dec 2024 IST

-1.06

(-100%)

Market is closed - opens 7 PM, 07 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 18 Dec 2024

View live Vaccinex Inc share price in Dollar and Rupees. Guide to invest in Vaccinex Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Vaccinex Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Vaccinex Inc (VCNX) Key Statistics

in dollars & INR

Previous Close
$1.06
Open
$1.0
Market Capitalization
$3.8M
Today's Volume
$50.9K
Revenue TTM
$356.0K
EBITDA
$-21.5M
Earnings Per Share (EPS)
$7.42
PE Ratio
0.19
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-759.09%

How to invest in Vaccinex Inc Stock (VCNX) from India?

It is very easy for Indian residents to invest directly in Vaccinex Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Vaccinex Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Vaccinex Inc or VCNX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Vaccinex Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Vaccinex Inc shares which would translate to null fractional shares of Vaccinex Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Vaccinex Inc, in just a few clicks!

Global Institutional Holdings in Vaccinex Inc

  • Point72 Asset Management, L.P.

    6.20%

  • Armistice Capital, LLC

    6.13%

  • UBS Group AG

    0.13%

  • Tower Research Capital LLC

    0.07%

Analyst Recommendation on Vaccinex Inc

Rating
Trend

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 7 Wall street analysts offering stock ratings for Vaccinex Inc(by analysts ranked 0 to 5 stars)

About Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Organization
Vaccinex Inc
Employees
37
CEO
Dr. Maurice Zauderer Ph.D.
Industry
Health Technology

Management People of Vaccinex Inc

NameTitle
Dr. Maurice Zauderer Ph.D.
Co-Founder, CEO, President & Director
Dr. Elizabeth E. Evans Ph.D.
COO and Senior VP of Discovery & Translational Medicine
Dr. Ernest S. Smith Ph.D.
Senior VP of Research & Chief Scientific Officer
Ms. Jill Sanchez CPA
Chief Financial Officer
Dr. John E. Leonard Ph.D.
Senior Vice President of Development

Important FAQs about investing in VCNX Stock from India :

Can Indians buy Vaccinex Inc shares?

Yes, Indians can invest in the Vaccinex Inc (VCNX) from India.

With INDmoney, you can buy Vaccinex Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Vaccinex Inc at zero transaction cost.

How can I buy Vaccinex Inc shares from India?

It is very easy to buy Vaccinex Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Vaccinex Inc (VCNX) be purchased?

Yes, you can buy fractional shares of Vaccinex Inc with INDmoney app.

What are the documents required to start investing in Vaccinex Inc stocks?

To start investing in Vaccinex Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Vaccinex Inc?

Today's market capitalisation of Vaccinex Inc VCNX is 3.8M

Who is the Chief Executive Officer (CEO) of Vaccinex Inc ?

Dr. Maurice Zauderer Ph.D. is the current Chief Executive Officer (CEO) of Vaccinex Inc.